Long Term Cancer Side EffectsAFTERGYNNCT05731661

Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase

A study testing Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse, Delivery of useful information according to support care needs, concerning support care professionals in the city and Delivery of a personalized post-cancer plan in people with Long Term Cancer Side Effects and Supportive Care in Cancer, run by Centre Francois Baclesse at 1 site in France.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

While the sequelae and toxicities after ovarian and endometrial cancer treatments are well described in the literature, the actual needs of patients for supportive oncology care remain poorly documented. Read more about this study

Who is it for?: Ages 18 years and older, women only
Conditions the study is for: Long Term Cancer Side Effects, Supportive Care in Cancer, Cancer Survivorship Care Plan
What is being tested?: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse, Delivery of useful information according to support care needs, concerning support care professionals in the city and Delivery of a personalized post-cancer plan
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 99 participants
Where: 1 siteFrance
Study dates: 9 Jan 2023to 25 Feb 2027
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
Women only
No healthy volunteers
Adult, Older adult

Who may be able to join

Patient > 18 years old
Patient in complete remission after first-line treatment for endometrial or ovarian/fallopian tube/peritoneal cancer
Patient having completed her initial treatment; patients with maintenance treatments are eligible
Mastery of the French language
Patient with a telephone line
Patient affiliated to a social security scheme
Signature of informed consent before any specific procedure related to the study

Who cannot join

Any associated medical or psychiatric conditions that could compromise the patient's ability to participate in the study
Patient with locoregional or metastatic recurrence
Patient deprived of liberty, under guardianship or curatorship
Simultaneous participation in a therapeutic clinical trial

Trial locations and contacts

1 site in 1 country.

France1 site

Centre Francois Baclesse
Caen, 14076

Other trials in France

About this study

It is expected that an evaluation of the needs for supportive oncology care and its organization in day hospitalization for supportive oncology care will lead to an improvement in personalized post-cancer follow-up for these patients and to an improvement in their long-term quality of life.

Conditions: Long Term Cancer Side Effects, Supportive Care in Cancer, Cancer Survivorship Care Plan, Advanced Nurse Practitioner, Pelvic Gynecological Cancer
Being tested: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse, Delivery of useful information according to support care needs, concerning support care professionals in the city, Delivery of a personalized post-cancer plan

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurseOther
During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
Delivery of useful information according to support care needs, concerning support care professionals in the cityOther
Delivery of useful information according to support care needs, concerning support care professionals in the city
Delivery of a personalized post-cancer planOther
Delivery of a personalized post-cancer plan

Study groups in NCT05731661
Study group	Role	What they receive
Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care	Experimental	Not described Receives: Other: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse; Other: Delivery of a personalized post-cancer plan
Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care	Active comparator	Not described Receives: Other: Delivery of useful information according to support care needs, concerning support care professionals in the city; Other: Delivery of a personalized post-cancer plan
Observational cohort	Other	Not described Receives: Other: Delivery of a personalized post-cancer plan

What is being measured

The primary outcome is the main question the study is designed to answer.

Proportion of patients who used at least one of the oncology support services recommended in the Personalized After-Cancer Care Plan within 4 months of receiving the Personalized After-Cancer Care Plan
Measured: Up to 4 months

Secondary outcomes (3)

Proportion of patients with sequelae after the initial treatment of their cancer, as well as the type and grade of the sequelae, based on the National Cancer Institute's screening grids (levels 1 and 2) during the consultation with a nurse referent
Measured: Up to 4 months
Description of the types of oncological support care needs identified
Measured: Up to 4 months
Proportion of patients with identified cancer care needs (at least one cancer care need to be implemented) 4 months after the submission of the Personalized Cancer Care Plan
Measured: Up to 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

9 Jan 202325 Feb 2027

First posted16 Feb 2023
Study start9 Jan 2023
Primary completion20 Nov 2025
Study completion25 Feb 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Long Term Cancer Side EffectsStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind
Who is masked: Participant
Enrolment: 99 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05731661
Sponsor's protocol ID: 2022-A01872-41
Acronym: AFTERGYN
Status last verified: Jan 2026
First submitted: 23 Jan 2023
Last updated: 15 Jan 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ovarian Neoplasms, Breast Neoplasms
Active, not recruitingObservational study
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
Breast Cancer
Not yet recruitingObservational study
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
RecruitingObservational study
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Breast Cancer Females
Active, not recruitingObservational study
Nutrition and Inflammation in Patients With Head and Neck Cancer
Head and Neck Neoplasms, Radiotherapy Side Effect

All Long Term Cancer Side Effects trials

Study at a glance

From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase
ClinicalTrials.gov ID: NCT05731661
Acronym / sponsor ID: AFTERGYN / 2022-A01872-41
Conditions: Long Term Cancer Side Effects, Supportive Care in Cancer, Cancer Survivorship Care Plan, Advanced Nurse Practitioner, Pelvic Gynecological Cancer
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 99 participants (estimated)
Lead sponsor: Centre Francois BaclesseUniversity, hospital or other
Collaborators: Ligue contre le cancer, France
Study start: 9 Jan 2023 (actual)
Primary completion: 20 Nov 2025 (actual)
Study completion: 25 Feb 2027 (estimated)
First posted: 16 Feb 2023 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind (participant)
Number of arms: 3

Arm	Type	Receives
Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care	Experimental	Other: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse, Other: Delivery of a personalized post-cancer plan
Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care	Active comparator	Other: Delivery of useful information according to support care needs, concerning support care professionals in the city, Other: Delivery of a personalized post-cancer plan
Observational cohort	Other	Other: Delivery of a personalized post-cancer plan

Who may qualify

Ages: 18 years and older
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Patient > 18 years old
Patient in complete remission after first-line treatment for endometrial or ovarian/fallopian tube/peritoneal cancer
Patient having completed her initial treatment; patients with maintenance treatments are eligible
Mastery of the French language
Patient with a telephone line

Key exclusion criteria (4 listed)

Any associated medical or psychiatric conditions that could compromise the patient's ability to participate in the study
Patient with locoregional or metastatic recurrence
Patient deprived of liberty, under guardianship or curatorship
Simultaneous participation in a therapeutic clinical trial

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurseDuring this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.	Other	Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care
Delivery of useful information according to support care needs, concerning support care professionals in the cityDelivery of useful information according to support care needs, concerning support care professionals in the city	Other	Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care
Delivery of a personalized post-cancer planDelivery of a personalized post-cancer plan	Other	Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care, Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care, Observational cohort

Primary outcome

Proportion of patients who used at least one of the oncology support services recommended in the Personalized After-Cancer Care Plan within 4 months of receiving the Personalized After-Cancer Care Plan
Time frame: Up to 4 months

3 secondary outcomes

Proportion of patients with sequelae after the initial treatment of their cancer, as well as the type and grade of the sequelae, based on the National Cancer Institute's screening grids (levels 1 and 2) during the consultation with a nurse referent
Time frame: Up to 4 months
Description of the types of oncological support care needs identified
Time frame: Up to 4 months
Proportion of patients with identified cancer care needs (at least one cancer care need to be implemented) 4 months after the submission of the Personalized Cancer Care Plan
Time frame: Up to 4 months

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
Individual participant dataSharing planned: No

Related trials for Long Term Cancer Side Effects

RecruitingPhase 2
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ovarian Neoplasms, Breast Neoplasms
Active, not recruitingObservational study
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
Breast Cancer
Not yet recruitingObservational study
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
RecruitingObservational study
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Breast Cancer Females
Active, not recruitingObservational study
Nutrition and Inflammation in Patients With Head and Neck Cancer
Head and Neck Neoplasms, Radiotherapy Side Effect

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients who used at least one of the oncology support services recommended in the Personalized After-Cancer Care Plan within 4 months of receiving the Personalized After-Cancer Care Plan (time frame: Up to 4 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05731661.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.